

Oncology Advisory Committee

February 28, 2022
MEDITECH



Our Mission

The ONCAC mission is to **advance oncology informatics** throughout healthcare organizations and to **enhance safety and efficiency of oncology practices**. The ONCAC committee members will serve as subject matter experts and provide guidance, recommendations, and conceptualization on Oncology Best Practices through the use of MEDITECH software and provide feedback for the future design of the Oncology application.





Agenda

- Draft Treatment Plan Ordering
- Patient Reported Outcomes
- Survivorship Content
- Development Corner
 - Genomics



Oncology Treatment Plans: Draft Ordering

Steve Beninati, MEDITECH Analyst

John Gath, Healthcare IT Project Manager



What is Draft Ordering?

- The ability for providers to enter a treatment plan for a patient without signing orders right away.



Sterling, George
 45 M 12/14/1976
 PRE RCR ATLANTIC

Resus Status Not Ordered No Hx Avail
 5ft 8in 200lb BSA:2.04m² BMI:30.4kg/m²
 Allergy/Adv: ragweed pollen, Sulfa (Sulfonamide Antibiotics), Penicillins

MG0000070309

MR00108453
 D45649525

**Malignant neoplasm of left lung - Cisplatin & Gemcitabine
 Treatment 14 day**

* First Cycle Number
 * Start Date * x Cycles x1 x2 x3 x4

Order	SCH	Admin Days
Pre-Hydrations		
<input checked="" type="checkbox"/> Sodium Chloride w/Mannitol 0.9 % Sodium Chloride [0.9 % Sodium Chloride- Bih*] 400 mls at 1,600 ml/hr IV ONCE with mannitol 18,145 mg (200 mg per kg)		1
Pre-Medications		
<input checked="" type="checkbox"/> Ondansetron [Ondansetron Odt] 4 mg PO ONCE tab.rapdis	SCH	1
Label Comments		
Dose Instruction		
dexAMETHasone		
<input type="checkbox"/> 2 mg PO PRECHEM tablet	SCH	
diazePAM [diazePAM*]		
<input type="checkbox"/> 5 mg PO PRECHEM tablet	SCH	
Chemotherapy		
<input checked="" type="checkbox"/> CISplatin (Platinol) 100 mg (70 mg/m ²) in Dextrose 5 % and 0.3 % NaCl [Dextrose 5%-0.33% NaCl IV Soln] 250 mls infuse over 1 hr IV ONCE		1
<input checked="" type="checkbox"/> gemcitabine hcl (Gemzar) 1,045 mg (500 mg/m ²) in Sodium Chloride 0.45% [Sodium Chloride] 500 mls		1



Sterling, George
 45 M 12/14/1976
 PRE RCR ATLANTIC

Resus Status Not Ordered No Hx Avail
 5ft 8in 200lb BSA:2.04m² BMI:30.4kg/m²
 Allergy/Adv: ragweed pollen, Sulfa (Sulfonamide Antibiotics), Penicillins

MG0000070309

MR00108453
 D45649525

Back Submit

**Malignant neoplasm of left lung - Cisplatin & Gemcitabine
 Treatment 14 day**

Cycle	1
Start Date	02/28/2022
x Cycles	x3

Status Order Draft

Treatment 14 day	Admin Days
Pre-Hydrations	
Sodium Chloride w/Mannitol 0.9 % Sodium Chloride [0.9 % Sodium Chloride- Bih*] 400 mls at 1,600 ml/hr IV ONCE with mannitol 18,145 mg (200 mg per kg)	1
Pre-Medications	
Ondansetron [Ondansetron Odt] 4 mg PO ONCE tab.rapdis SCH	1
Chemotherapy	
CISplatin (Platinol) 100 mg (70 mg/m ²) in Dextrose 5 % and 0.3 % NaCl [Dextrose 5%-0.33% NaCl IV Soln] 250 mls infuse over 1 hr IV ONCE	1
gemcitabine hcl (Gemzar) 1,045 mg (500 mg/m ²) in Sodium Chloride 0.45% [Sodium Chloride] 500 mls infuse over 1 hr IV ONCE	1
Diagnostics	
Complete Blood Count Man Dif [HEME] Routine	1

Sterling, George

45 M 12/14/1976
PRE RCR ATLANTIC

Resus Status Not Ordered No Hx Avail

5ft 8in 200lb BSA:2.04m² BMI:30.4kg/m²

Allergy/Adv: ragweed pollen, Sulfa (Sulfonamide Antibiotics), Penicillins

MG0000070309

MR00108453

D45649525

Options

Description	Diagnosis Date	Start Date	End Date	Status
▼ Malignant neoplasm of left lung - Stage IIB	Dx/TNM			Add
▼ Metastatic				
▼ Cisplatin & Gemcitabine [Ver 1]	T I			Active ▼
Chemo Cycle 1: Treatment 14 day	CV	02/28/2022	03/13/2022	Draft ▼
Chemo Cycle 2: Treatment 14 day	CV	03/14/2022	03/27/2022	Draft ▼
Chemo Cycle 3: Treatment 14 day	CV	03/28/2022	04/10/2022	Draft ▼
Chemo: Treatment 14 day				Start
Chemo: Treatment 21 day				Start

Sterling, George

45 M 12/14/1976
PRE RCR ATLANTIC

Resus Status Not Ordered No Hx Avail

MG0000070309

5ft 8in 200lb BSA:2.04m² BMI:30.4kg/m²

Allergy/Adv: ragweed pollen, Sulfa (Sulfonamide Antibiotics), Penicillins

Show
Can/DC

Transition Orders	Recalculate Orders	Edit Orders	DC Orders	Move Orders	Hold Orders	Resume Orders	Move Cycle	Hold Cycle	Resume Cycle	Stop Plan/Cycle
----------------------	-----------------------	----------------	--------------	----------------	----------------	------------------	---------------	---------------	-----------------	--------------------

	02/28/2022 Mon	03/14/2022 Mon	03/28/2022 Mon
 ▼ Malignant neoplasm of left lung - Stage IIB Metastatic Cisplatin & Gemcitabine <input type="checkbox"/> Dx/TNM <input type="checkbox"/> T <input type="checkbox"/> I			
Chemo	C 1 Day 1 Draft	C 2 Day 1 Draft	C 3 Day 1 Draft
▼ Pre-Hydrations			
0.9 % Sodium Chloride- Bih* with mannitol	400 mls IV 18,145 mg 200 mg per kg	400 mls IV 18,145 mg 200 mg per kg	400 mls IV 18,145 mg 200 mg per kg
▼ Pre-Medications			
Ondansetron Base	4 mg PO	4 mg PO	4 mg PO
▼ Chemotherapy			
CISplatin (Platinol)	100 mg IV 70 mg/m ²	100 mg IV 70 mg/m ²	100 mg IV 70 mg/m ²
gemcitabine hcl (Gemzar)	1,045 mg IV 500 mg/m ²	1,045 mg IV 500 mg/m ²	1,045 mg IV 500 mg/m ²
▼ Diagnostics			
Complete Blood Count Man Dif	Routine	Routine	Routine

Sterling, George

45 M 12/14/1976

PRE RCR ATLANTIC

Resus Status Not Ordered No Hx Avail

5ft 8in 200lb BSA:2.04m² BMI:30.4kg/m²

Allergy/Adv: ragweed pollen, Sulfa (Sulfonamide Antibiotics), Penicillins

MG0000070309

MR00108453

D45649525

Options

Description	Diagnosis Date	Start Date	End Date	Status
▼ Malignant neoplasm of left lung - Stage IIB	Dx/TNM			Add
▼ Metastatic				
▼ Cisplatin & Gemcitabine [Ver 1]	T I			Active ▼
Chemo Cycle 1: Treatment 14 day	CV	02/28/2022	03/13/2022	Edit/Order Undo Draft ▼
Chemo Cycle 2: Treatment 14 day	CV	03/14/2022	03/27/2022	
Chemo Cycle 3: Treatment 14 day	CV	03/28/2022	04/10/2022	Draft ▼
Chemo: Treatment 14 day				Start
Chemo: Treatment 21 day				Start



Use Cases:

- Providers signing per cycle rather than right away
- Non-provider users entering draft for providers to sign at a later time
- Entering a plan while awaiting test results

A top-down view of a dark, textured desk with various items: a smartphone on a notebook, a stethoscope, a tablet, a pencil, and a glass of water.

John Gath and Frederick Health on workflows
and experiences with Draft Ordering



Patient Reported Outcomes Measures Enhancing Clinical Decision Support

Scott Godbout, Solutions Manager, Strategy

Patient Reported Outcomes Measures PROMs

NCCN Best Practices (2021)

- Moving Towards a Patient-Centered Measurement System
- Value Based Care Pressures from Payers
- Quality Advancement initiatives
- Improving Affordability



Alignment for Enhanced Outcomes


CURRENT

- Process metrics from claims data serve payers not patients
- Measurement serves provider oversight, adds administrative burden
- Current metrics do not advance VBC programs (OCM)

FUTURE

- Intentional where metrics reflect patient-centered priorities
- Help clinical teams deliver more personalized care tx. & planning
- PROMs drive improvements in Value for society & patients & Advance DEI Goals

Use Cases



3 patient-reported outcome-based performance Measures

- *Health-Related quality of life (Distress)*
- *Pain*
- *Fatigue*
- + Financial Toxicity

Additional use cases:

- Rate of Growth in Oral Chemotherapy prescribing - Med Reconciliation Challenges
- SDoH implications - Access, financial means, transportation
- Future: Decentralized Clinical Trials (DCT's)

Schedule

February

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	13	14	15	16	17	18
20	21	22	23	24	25	26

Friday
Feb 18
 2022 08:36

Oncologists Print Calendar Today

Friday, February 18, 2022 Time

10:00	Bina Landry 781-484-2832 Home [60] Godbout,Scott	49 F 04/19/1972	Arrived - 00:10
11:00	Kingsbury Walter I 318-383-4756 [60] Godbout,Scott	69 M 07/01/1952	Booked Portal: Pending

Workload

- > Health Portal Messages 1 of 1
- > Oncology 68 of 68 !
- > Other 2 of 2 !

To Do 0

Quick Links

- National Cancer Institute (NCI)
- Clinical Trials.gov
- NCCN Treatment Plans



Walter Kingsbury



Messages



Health Record



Health Tracker



Appointments



Billing



Profile

60 Minute Follow Up at Oncology Practice (Clinic) on 02/18/2022
at 11:00 am EST

Pre-register

Schedule an Appointment

Select this option if you would like to schedule an appointment with one of our healthcare professionals.

[Schedule Appointment](#)

See a Provider Now

Select this option if you would like to see one of our providers now using our video conferencing technology.

[Get Started](#)

Announcements

!!COVID-19 Warning!!

If you think you have been exposed to COVID-19 and develop a fever and symptoms, such as cough or difficulty breathing, call your provider for medical advice.

"Covid Vaccines & Boosters are now available, schedule your appointment today using the Appointments tab in the Patient Portal"

If you have trouble opening links on the Patient Portal, please enable your computer or device to allow pop-up windows.

What's New Within the Last 90 Days

You have new Appointment activity.

You have new Questionnaire activity to complete by February 19, 2022.



Walter Kingsbury's Appointments

View the details of your appointment. Select 'Reschedule' or 'Cancel' to modify the appointment. [Learn More](#)

60 Minute Follow Up

Friday, February 18, 2022 at 11:00 am EST

Scott Godbout

Oncology Practice (Clinic)

Duration

60 minutes

To do prior to your appointment:



Pre-Registration Completed

Start

Covid-19 Screening

Start

Cancer Distress Screening



[Back to List of Appointments](#)



[Print](#)

[Contact Technical Support](#)



Walter Kingsbury's Questionnaires

Cancer Distress Screening

Answer the questions to complete your questionnaire.

Step 1 of 1: Cancer Distress Screening

Portal Responses:

I have felt anxious or worried about cancer and the treatment I am receiving.

<None>

I have felt depressed or discouraged.

<None>

I have been irritable or unusually angry, and I have not controlled it well.

<None>

My sleeping habits have changed.

<None>

<None>

1

2

3

4

5

All the time

Not at all

Cancel

Save Draft

Submit



Walter Kingsbury's Appointments

View the details of your appointment. Select 'Reschedule' or 'Cancel' to modify the appointment. [Learn More](#)

60 Minute Follow Up

Friday, February 18, 2022 at 11:00 am EST

Scott Godbout

Oncology Practice (Clinic)

Duration

60 minutes

To do prior to your appointment:



Pre-Registration Completed

Start

Covid-19 Screening



Cancer Distress Screening Completed

[Contact Technical Support](#)



[Back to List of Appointments](#)



[Print](#)

Scott Godbout

Find Patient



Schedule Fri February 18, 2022 8:40a

Feb 2022

Sun	Mon	Tue	Wed	Thu	Fri	Sat
13	14	15	16	17	18	19

Today More

Dr. Godbout Time

10:00		Bina, Landry [Arrival 08:26]	04/19/1972 49 F Godbout,Scott	Arrived 00:13
11:00		Kingsbury, Walter I [Arrival 08:39]	07/01/1952 69 M Godbout,Scott	Arrived 00:00



Workload

Recently Accessed Close All

Name	Visit Date	Close Chart
Kingsbury, Walter I	02/18/22	<input type="checkbox"/>
Bina, Landry	02/18/22	<input type="checkbox"/>
Kornfeld, Julie		

Quick Links

- [ACCC](#)
- [ASCO](#)
- [Clinical Trials.gov](#)
- [NCCN](#)
- [Practice Analytics](#)

Scott Godbout

Find Patient

Schedule

Fri February 18, 2022 8:40a

Workload

Feb 2022 13

Questionnaires Kingsbury, Walter I - 02/18/22 11:00


Consume Patient Data Close

10:00 11:00

Last Activity	Status	Name	Available Date	Source
02/18/22	Completed	Cancer Distress Questionnaire	02/18/22	AMB Appt
	No Activity	Infectious Disease	02/18/22	AMB Appt

Close All Visit Date Close Chart 02/18/22 02/18/22

Consume Patient Data
Cancel
Save as Draft
Consume



Kingsbury, Walter I ⓘ
 69 M 07/01/1952
 02/18/22 11:00

✓ **Cancer Distress Questionnaire** ⓘ 📝

Previously Documented	Recall All	Patient Documented	Accept All	Final
-----------------------	-------------------------	--------------------	-------------------------	--------------

✓ **Cancer Distress Screening**

I have felt anxious or worried about cancer and the treatment I am receiving.			<None>	🗨️
I have felt depressed or discouraged.			<None>	🗨️
I have been irritable or unusually angry, and I have not controlled it well.			<None>	🗨️
My sleeping habits have changed.			<None>	🗨️
I have noticed a change in my appetite.		All the time	All the time	🗨️
I have had trouble focusing at work or at home, or on routine things such as reading the newsp...			<None>	🗨️
Cancer and its treatment have interfered with my daily activities.		2	2	🗨️
Cancer and its treatment have interfered with my family or social life.		1	1	🗨️
Cancer and its treatment have interfered with my sex life.			<None>	🗨️
Pain and discomfort have caused			<None>	🗨️

Oncology Visit - Follow Up

Preview Rapid Entry Typicals

Save Sign

Author: Scott Godbout

Last Saved at 02/18/22 08:43

Intake HPI **ONC Treatment Plan Summary** Questionnaires ROS Exam A/P Procedures Coding Departure

ONC Treatment Plan Summary Add Content

Tx Summary

Oncology Treatment

No Active Chemotherapy

Cancer Distress Screening

Portal Responses:

I have felt anxious or worried about cancer and the treatment I am receiving.
I have felt depressed or discouraged.
I have been irritable or unusually angry, and I have not controlled it well.
My sleeping habits have changed.
I have noticed a change in my appetite. All the time
I have had trouble focusing at work or at home, or on routine things such as reading the newspaper or watching television.
Cancer and its treatment have interfered with my daily activities. 2
Cancer and its treatment have interfered with my family or social life. 1
Cancer and its treatment have interfered with my sex life.
Pain and discomfort have caused me to limit my activities.
Cancer has caused physical, emotional, or financial hardship for me. 4
Cancer and its treatment have caused changes in how I look, and this concerns me.
I have had trouble coping with the stress I have been having.
My quality of life during the past 2 weeks has been: 1
If you find that many of your answers are 4s or 5s, you may be having serious distress and should think about talking with a counselor or other mental health professional.

ONC ROS Add Content

Const
Aller/Immun
Eyes

Kingsbury, Walter I
69, M · 07/01/1952
MRN# IA00006616

Amb

Arrived REG AMB, HEMPRAC

Visit Date: 02/18/22

Full Code

Search Chart

Special Indicators

No Data to Display

Allergies

No Known Drug Allergies

Problems

HCC

Essential (primary) hypertension

Type 2 diabetes mellitus with unspecified complications

Unspecified osteoarthritis, unspecified site

Benign prostatic hyperplasia with lower urinary tract symptoms

Barrett's esophagus with dysplasia


Kingsbury, Walter I
 69, M · 07/01/1952
 MRN# IA00006616

Summary

Oncology Treatment Summary
 ONC DIAGNOSIS
 Carcinoma of rectum, stage 2
 STAGING
 No Active Chemotherapy

Personal Notes
 Walter is chairman of the Independence Day parade committee

Last Assessment and Plan
 Draft - 02/18/22 08:44
[Plan](#)

Visits

Future

Past One Year


DATE	LOCATION/ PROVIDER	PROBLEM
02/18/22	Oncology Infusion Center Godbout, Scott	Infusion 2hr
02/18/22	Oncology Practice (Clinic) Godbout, Scott	

Patient Demographics
 Employment: Shreve Island Elementary Sch

My Widget



WBC (4.8-10.8)	5.9 K/mm3	08/08/19
Plt Count (250-400)	316 K/mm3	08/08/19
Neut # (Auto) (2.27-7.68)	3.3 K/mm3	08/08/19
Hgb (14.0-18.0)	14.0 gm/L	08/08/19
Total Bilirubin (0.0-1.4)	0.8 mg/dL	08/08/19
Office Visit		10/28/19






Questionnaires Last Activity

Cancer Distress Questionnaire	 Consumed	02/18/22
Infectious Disease	No Activity	

Patient Widget
 No Data to Display

Documents Most Recent

Departmental		
Oncology/Hematology Visit		Today
Office Visit		10/28/19

Arrived REG AMB, HEMPRAC
 Visit Date: 02/18/22
[Full Code](#)
 
   

Special Indicators
 No Data to Display

Allergies
 No Known Drug Allergies

Problems

HCC

Essential (primary) hypertension
 Type 2 diabetes mellitus with unspecified complications
 Unspecified osteoarthritis, unspecified site
 Benign prostatic hyperplasia with lower urinary tract symptoms
 Barrett's esophagus with dysplasia

 She/Her/Hers
 Kornfeld, Julie
 F · 12/09/1962
 # IA00007360

Cancer Distress Questionnaire
 Kornfeld, Julie She/Her/Hers 59 F 12/09/1962 Allergy/Adv: basil (More) Close

Last Activity	Status	Appt Date Appointment	Visit Reason	Available Date	Source
02/11/22 	Consumed	02/11/22 60 Minute Follow Up	Oncology Follow Up Visit	02/10/22	AMB Appt
	No Activity	02/09/22 60 Minute Follow Up	Oncology Follow Up Visit	02/08/22	AMB Appt
01/12/22 	Consumed	01/12/22 60 Minute Follow Up	Oncology Follow Up Visit	01/12/22	AMB Appt
	No Activity	12/15/21 60 Minute Follow Up	Oncology Follow Up Visit	12/15/21	AMB Appt
10/05/21 	Consumed	10/05/21 30 Minute Follow Up	Oncology Follow Up Visit	10/05/21	AMB Appt
07/22/21 	Consumed	07/22/21 30 Minute Follow Up	Oncology Follow Up Visit	07/22/21	AMB Appt
06/18/21 	Consumed	06/18/21 30 Minute Follow Up	Oncology Follow Up Visit	06/18/21	AMB Appt
	No Activity	06/17/21 30 Minute Follow Up	Oncology Follow Up Visit	06/17/21	AMB Appt
06/10/21 	Consumed	06/10/21 30 Minute Follow Up	Oncology Follow Up Visit	06/10/21	AMB Appt
06/08/21 		06/08/21			

Summary

Summary

Oncology Treatment

ONC DIAGNOSIS
Malignant neoplasm of breast

STAGING
C: cT1 cN2 cM0 Stage Group

CLINICAL INDICATION
HER2 negative: Neoadjuvant

CYCLE NUMBER
2 of 2

CYCLE DAY
10 of 14

TREATMENT PLAN
Dose-Dense AC (DOXOrubicin)

CHEMOTHERAPY
DOXOrubicin hcl (Adriamycin)
cyclophosphamide (Cytoxan)

Personal Notes

Last Assessment and Plan

Visits

Future

Full Code

Indicators

Rash

HCC

cytotoxic drug

plasm of breast 0.153

ons

ption Monitoring Program

ED Discharge Packet 01/26/21

Office Visit 01/06/21

citalopram (Celexa)
10 mg (1/2 x 20 mg) PO BID

triamcinolone acetone 0.1%



Return To



Chart



Oncology



Chart Viewer



Close



Kornfeld,Julie

59 F 12/09/1962 She/Her/Hers
REG RCR HEMC

Full Code

5ft 7in 139lb BSA:1.73m² BMI:21.8kg/m²
Allergy/Adv: basil

EB0000037811

IA00007360

100008109

Show Summary

15 Min 30 Min 1 Hr 4 Hr 12 Hr 24 Hr Graph Graph Vitals

Flowsheets Recompile

Breast Cancer		02/11/22 Fri	02/09/22 Wed	02/08/22 Tue	01/27/22 Thu	01/12/22 Wed	12/15/21 Wed	10/05/21 Tue
Other Visits								
Treatment Plans								
Malignant neoplasm of breast Stage cIIA								
HER2 negative: Neoadjuvant Dose-Dense AC (DOXOrubicin/Cyclophosphamide) then PAclitaxel bi-weekly			Cycle 2 Day 1					
Chemotherapy								
cyclophosphamide (Cytoxan)								1,000 mg 600 mg/m² Started
DOXOrubicin hcl (Adriamycin)								
Medications Administered								
Prescriptions (non-chemo)								
Dexamethasone								10 mg Given
Distress Screening								
I have felt anxious or worried about cancer and th...		Not at all				Not at all		
I have felt depressed or discouraged.		1				1		
Nursing Documentation								
Chemotherapy Consent Form Signed						Yes		Yes
Pain Intensity						2		3
Other concern:						Mouth Pain		Mouth Pain
ECOG								
ECOG Performance Status					0	0		0
Height/Weight								
Height		5 ft 7 in	5 ft 7 in	5 ft 7 in	5 ft 7 in	5 ft 7 in	5 ft 7 in	5 ft 7 in
Weight		139 lb	120 lb	139 lb 15.897 oz	140 lb	140 lb	140 lb	140 lb
Vital Signs								
Temperature								98.6 F
Pulse Rate						75	75	75
Respiratory Rate						15	15	15
Blood Pressure						110/80	110/80	100/80
O2 Sat by Pulse Oximetry								
Hematology								
Hematology								
WBC								
RBC								
...								

The Building Blocks Of PROMs

- Patient & Consumer Health Portal
- Ambulatory Questionnaires
- Oncology Flowsheet
- **Next Up: Patient Registries**





Survivorship: Bladder Cancer

Nhien Bui, Product Manager

MEDITECH
EXPANSE

HPI - Bladder Cancer Follow-Up

Urinary complaints All

dysuria hematuria

Urinary frequency (per day)

<2 3-5 6-8 >8

Since the last visit, has the patient been treated for a UTI

Yes No

Bone pain

Yes No

Health Management		
Viewing: S-Bladder: NMI Cystecto	protocol by	Overview
Creatinine	-	PRN
Glucose	-	PRN
Anion Gap	-	PRN
Carbon Dioxide	-	PRN
Chloride	-	PRN
Potassium	-	PRN
Sodium	-	PRN
Imaging	Last Done	Next Due
Urogram	-	02/22/22
Abdomen/Pelvis CT	-	02/22/22
Renal U/S	-	PRN
Diagnostics	Last Done	Next Due
Urinary Cytology	-	-
Pathology	Last Done	Next Due
UWC	-	-

Health Management Set

- Urogram (CTU or MRU)
 - Urogram CT
 - Urogram MRI
- Urethral wash cytology - pathology: Result Type vs Report Type?



Development corner

Nate Mettillie, Manager Development



A photograph of medical professionals in a clinical setting, with one person pointing at a tablet held by another. The image is overlaid with a teal gradient.

Oncology Development Roadmap

Complete

- PoC w/ ONC
- Pharmacy / Oncology integration improvements
- Weight Method per Drug
- Apply Edits to Future Draft Cycles
- Launch to Acute Ordering from AMB

In Process

- **Genomics Integration and Decision Support**
- Inpatient Chemo Administration improvements
- Staging integration with PTH/mTuitive
- Height/Weight Across ONC Accounts
- Launch to Sched Grid from ONC

Upcoming

- More Flexibility to Transition Orders
- eClaims interface in Ontario

Determining

- Early Adopter Feedback
- Standard Content for Survivorship Surveillance
- Radiation Oncologist Workflow integration
- Improving Oral Chemo
- Problem List Improvements
- Oncology Data Integration with BCA



Genomics Integration and Decision Support

Heidi Sokoloski, MEDITECH Development - Software Designer



Challenges with Genetic Results

- No discrete data
- Hard to find in the Chart
- Rapidly changing industry
- Difficult to interpret



GENOMICS GOALS

New Genetics Application - LIS application to assist with specialized workflow including consuming and storing genetic data discretely

Standard Interfaces: To manage sending orders and receiving results of complicated genetics data and PDF reports

Identify Genetic Markers- Storing selective genetic markers as part of patient record with enhanced display in the Chart

Clinical Decision Support- Using data for clinical decision pharmacogenomics support at the point of ordering

Diagnostics Provider Notes Nurse/Allied Health Medications
History & Problems Administrative Other Clinical
Summary Activity Flowsheets Health Mgmt

Testarossa, Adam
 36, M · 06/06/1983
 MRN# CR00004200

Diagnostics Subcategory
 All Activity : All Time : Selected Laboratory 4 Hours Filter
Laboratory Imaging Microbiology Pathology Blood Banks Tests Cardiovascular Other Specialty

ADM IN, 1E.CH 5B -2
 Acc# CH0000000063 Resus Status Not Ordered
 No Hx Avail

Fullscreen ↗
All
Hematology
Chemistry
Serology
Genetics

Genetic Orders

Order	Result	Report	Date	Linked Specimen
Chronic Myeloid Leukemia Cytogenetic Specimen Molecular Specimen	Abnormal A See Interpretation		07/13/2019 07/13/2019	
Tumor MMR (IHC)	Loss of MSH2/MSH6		06/20/2019	PTH Surgical Specimen
Bld HPNCC Lynch Syndr Seq	Loss of MSH2/MSH6		06/20/2019	PTH Surgical Specimen

Search Chart 🔍

Patient's Genetic History
Germline

Gene /ROI	Genetic Findings/Genotype	Phenotype	Report	Date
CYP2C19	*2/*3	Poor Metabolizer	A	04/21/2015
CYP2C9	*57/01	Rapid Metabolizer		04/21/2015

Somatic

Gene /ROI	Genetic Findings	Report	Date
DNMT3A			07/13/2019

Allergies
 potassium (From Potassimin)
 lidocaine
 budesonide (From Pulmicort)
 meperidine (From Demerol)

Medications
Active
 acetaminophen 325 mg PO Q6H PRN
 acetaminophen clavulanate 125-



Where are we going?

- Result Prioritization
- Suggested Therapies
- Suggested Clinical Trials
- Updated Industry Details on Variants
- Genetic Results with Oncologist Workflow



Interactive Poll:

- We have access to details such as:
 - Pathogenic / Benign
 - Protein Effect
 - Oncogene/Tumor Suppressor etc.

Where would you like to see details on a genetic result?

Sample Questions in Upcoming Research

- Do genetic results need to be available during Treatment Plan Ordering, or just within the Chart?
- What level of detail is desired for the Genetic Results? Which details are the most important?
- We will have the ability to get suggested therapies based on the genetic results. How should this look and where should it be?
- We will be able to suggest Clinical Trials based on genetic results and diagnosis. When in the process should these be suggested?

Development Corner: Active Research

- Radiation Oncologist Workflows
 - Designer: Michelle Spurr - mspurr@meditech.com
- Genomics and Oncology
 - Designer: Heidi Sokoloski - hsokoloski@meditech.com
- Standard Survivorship Content
 - Product Manager - Nhien Bui - nbui@meditech.com

General Oncology Development and Strategy contacts:

Nate Mettille
Manager Development, Oncology
nmettille@meditech.com

Michelle Nabors
Supervisor Development, Oncology
mnabors@meditech.com

Scott Godbout
Product Manager - Oncology
sgodbout@meditech.com



QUESTIONS?

Next ONCAC meeting May 17th, 2022

MEDITECH

Oncology Resources

- [Oncology Advisory Committee \(ONCAC\) Webpage](#)
- [MEDITECH On Demand](#)
- [Oncology Featured Knowledge Base Articles](#)
- [Product Resource Pages](#)
 - **All Product Lines available**
- [Expanse End-User Based Roles Resources](#)

A close-up photograph showing a caregiver in a blue uniform supporting an elderly person. The caregiver's hands are gently holding the elderly person's arms, and the elderly person is holding a wooden cane. The scene is set against a dark, blurred background.

THANK YOU

MEDITECH